Oncotarget

Research Papers:

miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression

Hongtuan Zhang, Shiyong Qi, Tao Zhang, Andi Wang, Ranlu Liu, Jia Guo, Yuzhuo Wang and Yong Xu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:6092-6104. https://doi.org/10.18632/oncotarget.3341

Metrics: PDF 2361 views  |   HTML 2012 views  |   ?  


Abstract

Hongtuan Zhang1,2,3, Shiyong Qi1, Tao Zhang1, Andi Wang1, Ranlu Liu1, Jia Guo2, Yuzhuo Wang2,3 and Yong Xu1

1 Department of Urology, National Key Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China

2 Vancouver Prostate Centre & Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

3 Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Correspondence to:

Yong Xu, email:

Keywords: miRNA, metastasis, miR-188-5p, prostate cancer, LAPTM4B

Received: December 14, 2014 Accepted: January 03, 2015 Published: January 21, 2015

Abstract

Elucidation of the molecular targets and pathways regulated by the tumour-suppressive miRNAs can shed light on the oncogenic and metastatic processes in prostate cancer (PCa). Using miRNA profiling analysis, we find that miR-188-5p was significantly down-regulated in metastatic PCa. Down-regulation of miR-188-5p is an independent prognostic factor for poor overall and biochemical recurrence-free survival. Restoration of miR-188-5p in PCa cells (PC-3 and LNCaP) significantly suppresses proliferation, migration and invasion in vitro and inhibits tumour growth and metastasis in vivo. We also find overexpression of miR-188-5p in PC-3 cells can significantly enhance the cells’ chemosensitivity to adriamycin. LAPTM4B is subsequently identified as a direct target of miR-188-5p in PCa, and is found to be significantly over-expressed in PCa. Knockdown of LAPTM4B phenotypically copies miR-188-5p-induced phenotypes, whereas ectopic expression of LAPTM4B reverses the effects of miR-188-5p. We also find that restoration of miR-188-5p can inhibit the PI3K/AKT signaling pathway via the suppression of LAPTM4B. Taken together, this is the first report unveils that miR-188-5p acts as a tumour suppressor in PCa and may therefore serve as a useful therapeutic target for the development of new anticancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3341